Loading...
•
Mar 31, 2024
Rigel Q1 2024 Earnings Report
Reported strong commercial demand with the highest number of TAVALISSE and REZLIDHIA bottles sold in a quarter since launch, along with a net loss of $8.2 million.
Key Takeaways
Rigel Pharmaceuticals reported Q1 2024 financial results, featuring strong commercial demand with record bottle sales for TAVALISSE and REZLIDHIA. Total revenues reached $29.5 million, with a net loss of $8.2 million, or $0.05 per share.
Total revenues were $29.5 million, including $21.1 million from TAVALISSE sales and $4.9 million from REZLIDHIA sales.
Net loss for the quarter was $8.2 million, or $0.05 per share, improved from a net loss of $13.5 million in the same period last year.
Total costs and expenses decreased to $36.5 million, driven by lower research and development costs and consulting fees.
Cash, cash equivalents, and short-term investments totaled $49.6 million as of March 31, 2024.
Revenue by Segment
Revenue by Geographic Location
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...